Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 5/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23721981 | 0.99 | ICMT (0.43) | ICMTGRIN2BROCK2ROCK1CNR2 | |
| SCHEMBL23745742 | 0.94 | ICMT (0.48) | ICMTGRIN2BCNR2CNR1KMT2A | |
| SCHEMBL23722107 | 0.94 | ICMT (0.48) | ICMTGRIN2BCNR2CNR1KMT2A | |
| Hydrochloric Acid SCHEMBL23721849 | 0.94 | ICMT (0.47) | ICMTGRIN2BCNR2CNR1KMT2A | |
| SCHEMBL23745589 | 0.89 | ICMT (0.40) | ICMTGRIN2BCNR2CNR1KMT2A | |
| SCHEMBL23721877 | 0.89 | ICMT (0.48) | ICMTGRIN2BCNR2CNR1KMT2A | |
| SCHEMBL23745895 | 0.89 | ICMT (0.49) | ICMTCNR2CNR1KMT2A | |
| SCHEMBL23745854 | 0.89 | ICMT (0.42) | ICMTGRIN2BCNR2CNR1KMT2A | |
| SCHEMBL23745855 | 0.89 | ICMT (0.42) | ICMTGRIN2BCNR2CNR1KMT2A | |
| SCHEMBL23745777 | 0.88 | ICMT (0.40) | ICMTGRIN2BCNR2CNR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | FDPS, FPR1, F12 | ICMT 345/4885GRIN2B 4667/4885ROCK2 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.